Prot# SL0010: A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of The Efficacy and Safety of four 12-week Treatment Cycles (48 weeks total) Of Epratuzumab in Systematic Lupus Erythematosus Subjects With Moderate To Severe Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date12/13/1112/13/14

Funding

  • Parexel (SL0010)
  • UCB Biosciences, Inc. (SL0010)